University Of California-San Francisco (UCSF) Translational Symposium, September 10, To Focus On HIV Breakthrough And Immune Function

September 09, 1998

UCSF will sponsor its 4th Annual Translational Research Symposium for HIV investigators on Thursday, September 10.

Titled "Antiretroviral Therapy: Preventing HIV Breakthrough & Rebuilding Immune Function," the one-day event will include a series of lectures reviewing the basic, clinical, and behavioral studies on the causes and consequences of virologic failure and the rebuilding of immune function.

The symposium is co-sponsored by the UCSF Center for AIDS Research and the AIDS Clinical Research Center, both programs of the UCSF AIDS Research Institute, and the Gladstone Institute of Virology and Immunology.

The program will take place in Cole Hall, UCSF Medical Sciences Building, 513 Parnassus Ave., San Francisco. MEDIA ARE INVITED TO COVER.

The program is as follows:

8:30-8:35 am
WELCOME -- Paul A. Volberding, MD, UCSF professor of medicine; director, UCSF Center for AIDS Research; director, UCSF AIDS Program and Medical Oncology at San Francisco General Hospital; and Warner C. Greene, MD, PhD, UCSF professor of medicine, microbiology and immunology; director, UCSF Center for AIDS Research; and director, Gladstone Institute of Virology and Immunology.

8:35-9:15 am
KEYNOTE ADDRESS: "Immunity to HIV--Does it Matter?" -- Bruce D. Walker, MD, director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School.


CAUSES AND CONSEQUENCES OF VIROLOGIC FAILURE

9:15-9:45 am
"LATENT RESERVOIRS FOR HIV-1: IMPLICATIONS FOR VIRUS ERADICATION" -- Robert Siliciano, MD, PhD, associate professor of medicine, John Hopkins University.

9:45-10:15 am
"HIV THERAPY: DYNAMICS, RESISTANCE AND RESERVOIRS" -- Doug Richman, MD, professor of pathology & medicine; co-director, Center for AIDS Research and AIDS Research Institute, UC San Diego.

10:15-10:45 am
DISCUSSION/BREAK

10:45-11:15 am
"TARGETING CELLULAR FACTORS: AN ALTERNATIVE TO CONTROL HIV REBOUND AND REBUILD IMMUNE FUNCTION"-- Franco Lori, MD, scientific director, Research Institute for Genetic Human Therapy, Georgetown University and Policlinico, San Matteo.

11:15-11:45 am
"BEHAVIOR AND BREAKTHROUGH" -- Frederick M. Hecht, MD, UCSF assistant professor of medicine.

Noon-1:00 pm
LUNCH BREAKOUT SESSIONS
  • Is Eradication Possible?
  • Immune Preservation After Virologic Failure
  • Extending Therapy to Developing Countries
REBUILDING IMMUNE FUNCTION

1:15-1:35 pm
"PREVALENCE OF ANTIVIRAL MEDICATION USE IN A PROBABILITY SAMPLE OF HIV SEROPOSITIVE MSMS IN MAJOR U.S. CITIES" -- Ronald D. Stall, PhD, MPH, UCSF associate professor of medicine.

1:35-1:55 pm
"PREVALENCE OF VIRAL DRUG RESISTANCE" -- Robert M. Grant, MD, MPH, MS, associate director, UCSF Center for AIDS Research; staff research scientist, Gladstone Institute of Virology and Immunology.

1:55-2:15 pm
"PREDICTING AND PREVENTING THE EMERGENCE OF ANTIRETROVIRAL DRUG RESISTANCE IN SAN FRANCISCO" -- Sally Blower, PhD, UCSF associate professor of microbiology, immunology and medicine.

2:15-2:45 pm
DISCUSSION/BREAK

2:45-3:15 pm
"VIRAL AND CELLULAR DYNAMICS IN HIV INFECTED LYMPHOID TISSUE" -- R. Pat Bucy, MD, PhD, associate professor of pathology, University of Alabama at Birmingham.

3:15-3:45 pm
"MONITORING OF THYMIC DEPENDENT T-CELL REGENERATION" -- Crystal Mackall, MD, investigator, Pediatric Oncology Branch, National Cancer Institute.

3:45-4:15 pm
"T-CELL PRODUCTION IN HIV-1 DISEASE" -- Joseph M. McCune, MD, PhD, associate investigator, Gladstone Institute of Virology and Immunology; UCSF associate professor of medicine.

4:15-4:30 pm
WRAP-UP -- Paul A. Volberding, MD, and Warner C. Greene, MD, PhD.

Media interested in covering the symposium, please call Corinna Kaarlela in the UCSF Mews Office at San Francisco General Hospital (415) 476-3804.
-end-


University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.